= Abstract = Transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS), and persistent pulmonary hypertension (PPHN) are the three most common disorders that cause respiratory distress after birth. An understanding of the pathophysiology of these disorders and the development of effective therapeutic strategies is required to control these conditions. Here, we review recent papers on the pathogenesis and treatment of neonatal respiratory disease. ( 
Introduction
Respiratory distress in newborn infants is common immediately after birth and is transient in most cases. However, when it persists, diagnostic procedures to determine the etiology and therapy are required to resolve the underlying problem. There are three common disorders that cause respiratory distress after birth: transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS) and persistent pulmonary hypertension (PPHN).
Here, recent papers on the pathogenesis and treatment of these neonatal respiratory diseases are reviewed.
Pathogenesis of disease 1 . Transient tachypnea of the newborn TTN is a parenchymal lung disorder characterized by pulmonary edema that results from delayed resorption and clearance of fetal alveolar fluid in term infants 1) . The excess fluid in the lungs in TTN results in decreased pulmonary compliance and increased airway resistance.
The mechanism causing changes in pulmonary function are primarily associated with the extrinsic compression of small airways by fluid in the extra-alveolar interstitium.
Tachypnea develops to compensate for the increased work of breathing associated with reduced compliance and increased airway resistance 2) .
Respiratory distress syndrome
RDS is also known as hyaline membrane disease; it is the major cause of neonatal respiratory distress, especially in preterm infants. RDS is caused by a deficiency of surfactant. Surfactant is a phospholipid mixture that is responsible for stabilizing distal alveoli, at low end-expiratory lung volumes, by reducing surface tension 3) . When surfactant is deficient, the infant may not be able to generate the increased inspiratory pressure required to inflate alveolar units, resulting in the development of progressive atelectasis. Diffuse atelectasis results in low compliance, high resistance in small airways, and low functional residual capacity. Hypoxemia results primarily from mismatching of ventilation and perfusion as blood bypasses the atelectatic air spaces. Right-to-left shunting then occurs through the ductus arteriosus and foramen ovale because of increased pulmonary vascular resistance (PVR) and contributes to the decreased oxygenation 3, 4) .
Persistent pulmonary hypertension
PPHN is caused by persistently elevated PVR that leads to right-to-left shunting through the foramen ovale and the ductus arteriosus, resulting in hypoxemia 5) . PPHN occurs primarily in term or late preterm infants (≥34 weeks gestation). The high pulmonary resistance is secondary to a number of factors, including: low arteriolar and alveolar oxygen levels; hypercarbia; acidosis; alveolar fluid pressure; lack of mechanical, rhythmic distention of the lung; and the net vasoconstricting action of a number of humoral agents. Catecholamines, histamine, bradykinin, angiotensin, adenosine, serotonin, prostaglandins, thromboxane, atrial natriuretic peptide, endothelin, and nitric oxide (NO) are involved in the regulation of pulmonary vascular tone in the fetus 6) . Newborns with PPHN are at risk of severe asphyxia and its complications including death, neurologic injury and other problems. Studies over the past two decades have clearly shown the critical role of NO-cGMP signaling in the regulation of the fetal and neonatal pulmonary circulation, and that disruption of the NO-cGMP cascade during the perinatal period leads to PPHN 7) .
Management of disease 1. Fluid restriction
Fluid restriction and metabolic monitoring are important components of patient management. Urine output typically is reduced in infants with respiratory distress, even when the cardiac output is adequate. Excessive fluid increases the risk of patent ductus arteriosus, necrotizing enterocolitis (NEC), and bronchopulmonary dysplasia (BPD). Furthermore, morbidity and mortality have been observed to be lower in premature patients that were fluid restricted compared to similar patients in whom fluid intake was not restricted 8) .
There is no evidence to support the routine use of diuretics in preterm infants with RDS. In addition, the administration of early nutrition is important in the overall care of these premature infants 9) .
Transient tachypnea of the newborn
Because TTN is a benign, self-limited condition, patient management is primarily supportive. .
2) Noninvasive mechanical ventilation
(1) Continuous positive airway pressure (CPAP) Among premature infants without respiratory failure, CPAP is an alternative to mechanical ventilation to prevent atelectasis; this might help avoid the increased risk of BPD associated with mechanical ventilation 14) . In larger babies with RDS, CPAP is the preferred treatment modality based on the data from a meta-analysis that showed a lower morbidity and mortality rate in infants with birth weights greater than 1,500 g that were treated with CPAP com- . Although the overall mortality rate and incidence of BPD does not differ between infants that received synchronized versus non synchronized ventilation, experts in the field suggest that synchronization may be useful in a subgroup of preterm infants below 28 weeks of age that are more susceptible to lung injury because of the shorter period of ventilation 18, 19) . ( .
(4) Volume-controlled (VC) ventilation
The clinician presets the tidal volume (generally 4 to 6 mL/kg), the respiratory rate, and an inspiratory time limit.
The duration of inflation is dependent upon the time to deliver the set tidal volume. However, the total volume may not be delivered if the preset inspiratory time limit is exceeded. The rate of flow, PIP, and inspiratory time may vary from breath-to-breath 23) . .
4) High frequency ventilation
High frequency oscillatory ventilation (HFOV), a method of providing rapid ventilation with very small tidal volumes, appeared to be a promising alternative as it reduced lung injury in animal models compared to conventional ventilation. However, nearly all trials comparing HFOV to conventional ventilation performed in preterm infants with RDS (since surfactant replacement therapy has been available) have shown no increased benefit with regard to mortality and the development of BPD 25) . At present, there is no evidence that favors the routine use of high frequency ventilation over conventional ventilation (CV). Nevertheless, when infants fail CV with persistent poor gas exchange and when PIP is equal to or greater than 30 cm H2O or the mean air pressure exceeds 12 cm H2O in infants, HFV offers an alternate mode of ventilation that may provide better ventilation and oxygenation in the neonate with severe respiratory disease 26) .
5) Inhaled nitric oxide (iNO)
It is well established that iNO provides benefit in the treatment of term or late preterm infants with persistent pulmonary hypertension. In addition, animal studies have demonstrated that iNO reduces lung inflammation, improves surfactant function, attenuates hyperoxic lung injury, and promotes lung growth 27) . A number of randomized controlled clinical trials have demonstrated that iNO did not increase the risk of short-term adverse events, particularly brain injury, and findings from one trial suggested that iNo may improve neurological outcomes in some premature infants 28) . However, the effective dose, duration, and time of administration of iNO are unknown. Based on currently available data, the routine administration of iNO to preterm infants with RDS is not recommended 29) .
6) Surfactant therapy
A wide variety of surfactant preparations that include natural and synthetic products, have been developed. Currently, only natural surfactant preparations are available 30) .
( The diagnosis is based on the infant's oxygen requirement, clinical examination, and chest radiographs [30] [31] [32] .
With all three strategies, surfactant therapy improves mortality and morbidity in preterm infants when compared to untreated patients. However, clinical trials suggest that prophylactic or early therapy is superior to rescue therapy alone in infants at high-risk for RDS (below 30 weeks gestation). In a meta-analysis, prophylactic administration of surfactant reduced the incidence of pneumothorax, pulmonary interstitial emphysema, and mortality when compared to the administration of surfactant for established RDS. The most striking reduction in mortality occurred in infants under 30 weeks of gestation [30] [31] [32] .
(4) Continued therapy
After the initial dose of surfactant is given for the treatment of RDS, the patient's response is assessed based on the continued oxygen requirements. Surfactant therapy is administered for a total of three to four doses based on the continued oxygen needs and the specific surfactant preparation used. Multiple doses of natural surfactants compared to a single dose leads to a lower frequency of pneumothorax. In addition, mortality is reduced in patients receiving surfactant therapy 32, 33) .
Persistent pulmonary hypertension
Treatment strategies for PPHN are directed at reducing PVR. Mechanical ventilation is typically needed early during the course of PPHN. High-frequency ventilation or surfactant may be beneficial in infants with parenchymal lung disease. Cardiac output should be supported with pressors and fluid administration 5, 6) .
1) Oxygen
Oxygen is a pulmonary vasodilator and initially should be administered in a concentration of 100 percent to infants with PPHN in an attempt to reverse pulmonary vasoconstriction. However, there is no advantage to maintaining an elevated PaO2. Thus, the PaO2 should be kept in the range of 50 to 90 mmHg (oxygen saturation >90 percent) to provide adequate tissue oxygenation and avoid lung injury that may result from continued administration of high concentrations of oxygen 6) .
2) Assisted ventilation
Because hypercarbia and acidosis increase PVR, the goal is to establish and maintain normal ventilation ( .
3) Surfactant
In a randomized trial of term infants with severe respiratory failure, surfactant administration significantly reduces the need for extracorporeal membrane oxygenation (ECMO) therapy (29 versus 40 percent with placebo), without increasing the risk of complications. However, there appears to be no effect when PPHN was the primary diagnosis (30 versus 32 percent) 35) .
4) Inhaled nitric oxide
Endogenous NO regulates vascular tone by causing relaxation of vascular smooth muscle. When inhaled, NO is a selective pulmonary vasodilator. Inhaled NO improves oxygenation and reduces the need for ECMO in term and late preterm infants with severe PPHN and does not appear to have toxicity 36) . In a randomized trial, early initiation of iNO in infants with mild to moderate respiratory impairment with an oxygenation index (OI) between 15 and 25, compared to the routine initiation at an OI >25, did not reduce the incidence of mortality or the need for ECMO therapy.
It also did affect the outcomes of neurodevelopment and hearing among the surviving infants evaluated at 18 to 24 months of age 37) .
